The objectives of this phase I/II study of irinotecan are: Phase I 1)To determine the MTD and DLT or irinotecan when administered every 3 weeks to patients with recurrent or progressive malignant gliomas who are receiving enzyme-inducing anti-epileptic drug (EIAED) therapy and those not on such agents. 2)To determine the safety profile of irinotecan given on this schedule in this patient population. 3)To characterize the pharmacokinetics of irinotecan and its metabolites on this schedule. 4)To assess antitumor activity. Phase II 1)To determine efficacy of irinotecan as measured by 6-month progression free survival and objective tumor response. 2)To evaluate further the safety profile of irinotecan in patients with glioma.
Showing the most recent 10 out of 859 publications